Cancer Drugs Fund rapid review of dasatinib for treating imatinib-resistant chronic myeloid leukaemia and for people for whom treatment with imatinib has failed because of intolerance (part review of NICE Guidance TA 241) and dasatinib for the first-line treatment of chronic myeloid leukaemia (part review of NICE Guidance TA 251). Decision Support Unit Report for the National Institute for Health and Care Excellence

Research output: Book/ReportCommissioned report

Original languageEnglish
PublisherNational Institute for Health and Care Excellence
Commissioning bodyNICE Decision Support Unit
Publication statusPublished - 2016

Cite this